In HCC, the upregulation of PD-1 and PD-L1 contributes to the suppression of antitumor immunity, but the development of PD-1 inhibitors has revolutionized the treatment of advanced HCC [36]. The gene discussed is CD274; the disease is hepatocellular carcinoma.